Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

 Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Medtronic Reports Results of VenaSeal Closure System in VeClose Extension Study for Chronic Venous Diseases

Shots:

  • The Veclose Extension study is a follow-on study of VeClose Study evaluating long-term outcomes at 5yrs. post-treatment with the VenaSeal Closure System in 56 patients with chronic venous disease resulted in 94.6% closure rate of the great saphenous vein (GSV)
  • The VeClose Study involves assessment of VenaSeal & ClosureFast radiofrequency ablation (RFA) device demonstrating vein closure 91.4% & 85.2% respectively for 5yrs.
  • The VenaSeal closure system is the non-tumescent, non-thermal, non-sclerosant procedure which utilizes a medical adhesive delivered endovenously to close the vein & eliminates the risk of nerve injury while treating saphenous vein

Click here to read full press release/ article | Ref: Medtronic | Image: Medtronic Endovenous

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post